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Background: Monitoring resistance phenotypes for Plasmodium falciparum, using in vitro growth assays, and
relating findings to parasite genotype has proved particularly challenging for the study of resistance to artemisinins.
Methods: Plasmodium falciparum isolates cultured from 28 returning travellers diagnosed with malaria were
assessed for sensitivity to artemisinin, artemether, dihydroartemisinin and artesunate and findings related to
mutations in pfatp6 and pfmdr1.
Results: Resistance to artemether in vitro was significantly associated with a pfatp6 haplotype encoding two amino
acid substitutions (pfatp6 A623E and S769N; (mean IC50 (95% CI) values of 8.2 (5.7 – 10.7) for A623/S769 versus 623E/
769 N 13.5 (9.8 – 17.3) nM with a mean increase of 65%; p = 0.012). Increased copy number of pfmdr1 was not itself
associated with increased IC50 values for artemether, but when interactions between the pfatp6 haplotype and
increased copy number of pfmdr1 were examined together, a highly significant association was noted with IC50
values for artemether (mean IC50 (95% CI) values of 8.7 (5.9 – 11.6) versus 16.3 (10.7 – 21.8) nM with a mean increase
of 87%; p = 0.0068). Previously described SNPs in pfmdr1 are also associated with differences in sensitivity to some
artemisinins.
Conclusions: These findings were further explored in molecular modelling experiments that suggest mutations in
pfatp6 are unlikely to affect differential binding of artemisinins at their proposed site, whereas there may be
differences in such binding associated with mutations in pfmdr1. Implications for a hypothesis that artemisinin
resistance may be exacerbated by interactions between PfATP6 and PfMDR1 and for epidemiological studies to
monitor emerging resistance are discussed.
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Identifying associations between genotypes of Plasmo-
dium falciparum and artemisinin resistance, however it
may be defined, is of paramount importance. Attempts
to demonstrate clear-cut associations between genotype
and phenotype are challenged by variable definitions of
clinical treatment failure [1], dormancy in immature
parasites that do not show increased in vitro resistance* Correspondence: sgjf100@sgul.ac.uk
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reproduction in any medium, provided the orto artemisinins but recrudesce after exposure to high
drug concentrations [2–4], and the absence of interpret-
ive breakpoints that demarcate susceptibility and resist-
ance to artemisinins.
Several years ago, PfATP6 was hypothesized to be, a
SERCA-type calcium pump of the parasite that was a po-
tential target for artemisinins [5]. One implication of this
hypothesis was that mutations in PfATP6 might influ-
ence susceptibility to artemisinins [6]. Decreased in vitro
sensitivity to artemisinins was later associated with
mutations in pfatp6 (particularly coding for an S769N
substitution) in some geographically and temporally. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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reports (reviewed in [10]) that do not associate other
SNPs in pfatp6 with decreased susceptibility to artemi-
sinins, perhaps because the detection of these associa-
tions may be confounded by the intrinsic polymorphic
tendency of this sequence [8,11,12] or lack of detailed
phenotypic characterizations. Alternative mechanisms
of action and resistance have also been examined for
artemisinins (reviewed in [10,13,14]), with these hy-
potheses having different implications for monitoring
of resistance and new drug development programmes.
Consequently, any evidence obtained from patient iso-
lates that can clarify relationships between parasite
genotypes and artemisinin sensitivity will be useful,
particularly as in vitro models may not be able to rep-
licate phenotypes of resistance to artemisinins observed
in clinical isolates.
Increased copy number for pfmdr1 is associated in
many geographic areas with elevations in IC50 values to
arylaminoalcohols (mefloquine and lumefantrine) and
artemisinins. These observations were first made in la-
boratory models of drug resistance and confirmed in iso-
lates from patients in Southeast Asia [15-18]. Increased
pfmdr1 copy number is established as a clinically relevant
determinant of treatment failure with mefloquine even
when given with artesunate [17,19]. Laboratory in vitro
and in vivo models have confirmed the causal link be-
tween pfmdr1 copy number and multidrug resistance
[20,21]. Amino acid substitutions in pfmdr1 may also
modulate drug susceptibility in clinical isolates [22,23].
Mechanisms of artemisinin resistance were studied in
travellers returning to Southern Ontario with a presump-
tive diagnosis of P. falciparum infection who had blood
specimens submitted to the Toronto Public Health La-
boratory for confirmation of diagnosis. As part of a study
to validate in vitro susceptibility testing for P. falciparum,
parasites were introduced into cultures and their drug
sensitivity profiles assessed. An early case report from
these efforts suggested that some parasites manifest
in vitro resistance to the artemisinin class of anti-malar-
ials [24], and that this phenotype could be linked to poly-
morphisms in pfatp6, and pfmdr1 copy number. This
report expands those preliminary findings and provides
results from approximately three times the number of
isolates originally examined. Here, the hypothesis that
particular mutations in pfatp6 are associated with eleva-
tions in IC50 values to some artemisinins is tested, and
the potential contribution of mutations in pfmdr1 to this
resistance phenotype is examined.
Methods
Parasites
Blood specimens were obtained from patients for routine
diagnostic purposes and placed into culture for in vitrodrug susceptibility assays or directly tested using an
ex vivo assay. Results for some of these parasites (n = 10)
have been previously reported [24]. This study was
approved by the Ethics Committee of Mount Sinai Hos-
pital (MSH REB #07-0337-E) in Toronto, Ontario.
Drug susceptibility assays
Ex vivo drug susceptibility testing was conducted in trip-
licate using fresh isolates from blood of patients with mi-
croscopy confirmed cases of P. falciparum [25]. Isolates
were diluted with uninfected blood to 0.05% - 0.2% para-
sitaemia and 1.5% haematocrit. An aliquot of 195 μL of
sample in RMPI 1640 and 0.5% Albumax I (Invitrogen)
was loaded into a 96-well plate and 5 μL of drug was
added with a Biomek 3000 (Beckman Coulter) auto-
mated liquid handler. Anti-malarial drugs, artemisinin
(Sigma-Aldrich 361593), artesunate (Sigma-Aldrich
A3731), dihydroartemisinin (DHA; SensaPharm RS-004)
and artemether (SensaPharm RS-010) were serially
diluted 1 in 5 from a stock solution of 250 μM in the
series: 6250, 1250, 250, 50, 10, 2, 0.4, 0.08 and 0.016 nM.
Plates were frozen for at least 24 h at −80°C after incuba-
tion at 37°C, 5%, CO2, 5%, O2 for 72 h and then thawed
and checked for complete lysis of erythrocytes before
analysis by HRPII ELISA assay [25]. All plates contained
a reference parasite strain for quality control purposes.
In vitro drug susceptibility tests were performed in
triplicate using cultured P. falciparum isolates. Isolates
were synchronized to achieve over 70% immature (ring)
stages and were diluted with uninfected erythrocytes to
1–1.2% parasitaemia and 0.5% haematocrit. Erythrocytes
and drugs were added and incubated as above for 72 h.
Erythrocytes were stained with SybrGreen I and analysed
by Beckman Coulter FC500 Flow Cytometer.
Sequence analysis for pfatp6 and pfmdr1 and copy
number assay
Pyrosequencing, using methodology described previously
[26], was used to detect a subset of known SNPs in genes
associated with resistance to anti-malarial drugs in P. falcip-
arum; such as mutations in codon 623 and 769 of the P. fal-
ciparum calcium-transporting ATPase gene (pfatp6,
Genbank ID EF564342.1) previously associated with resist-
ance to artemisinins [7,8]; mutations in codons 86, 184,
1034, 1042, and 1246 of the P. falciparum multi-drug resist-
ance protein 1 gene (pfmdr1) associated with resistance to
multiple anti-malarial drugs [27]. Briefly, biotinylated PCR
products, produced using a PyroMark PCR Kit (Qiagen),
were purified and captured on streptavidin sepharose beads
(GE Healthcare) through a vacuum preparation protocol.
They were then resuspended in sequencing primer solution,
denatured in a heat block and annealed to the sequencing
primer of interest. Forward, reverse and sequencing primers
are shown in Additional file 1. Sequencing assays were
Table 1 Pearson’s correlation coefficient (r) values (95%
CI) for IC50 comparisons of artemisinins
Drug Artesunate DHA Artemether
Artemisinin 0.47 (0.11 – 0.72)
p= 0.012
0.42 (0.05 – 0.68)
p= 0.028
0.65 (0.37 – 0.82)
p= 0.0002
Artesunate 0.66 (0.39 – 0.83)
p= 0.0001
0.60 (0.29 – 0.79)
p= 0.0008
DHA 0.33 (−0.05 – 0.63)
p= 0.084
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manufacturer’s protocol, and analyzed using the supplied
Q24 software. Also pfmdr1 copy number was determined
in combination with the SNPs to study the association be-
tween the increase in pfmdr1 gene copy number and drug
resistance [17].
Statistical analyses
Data were summarized in Excel and analysed in Graph-
Pad (Version 5.04). For the primary multiple compari-
sons (two-tailed, unpaired Student’s t-tests) involving
pfatp6 (A623E/S769N) and pfmdr1 copy number the
statistical significance level was set to p< 0.025. Other
comparisons are exploratory and presented without cor-
rection for multiple comparisons but with data made
available (Additional file 2). The assumption of normality
was tested with Kolmogorov-Smirnov test. Pearson’s
product moment coefficient was used to calculate corre-
lations. To assess if presenting parasitaemia may have
influenced results after normalizing in culture, values
<0.1% were set to 0.1% for statistical purposes. IC50
values were calculated by HN-nonlin v1.1 software [28].
Modelling and docking studies
The sequence of PfATP6 (UniProt Accession Number:
Q5R2K6) was obtained from the UniProt database ([29],
accessed 2 March, 2011) and is 1228 amino acids in
length. It was modelled, as previously reported in detail
[30], and the model deposited in the Protein Model Data
Base. It can be retrieved using the following IDs:
PM0077298 (PfATP6 in state E1) and PM0077299
(PfATP6 in state E2). Using this model, the effects of the
two SNPs that have been studied in this report (A623E
and S769N) were examined. The molecular structures of
artemether, artemisinin and DHA were retrieved from
the Cambridge Structural Database, and docked into
PfATP6, as previously described for artemether. Initially,
‘blind docking’ experiments were implemented and these
were followed by site-specific docking steps, using
AutoDock4.2.
The sequence of PfMDR1 (UniProt Accession Number:
P13568) detected PDB:3G5U (chain A) as the best tem-
plate (sequence identity: 31%, E-value< 10-10). 3G5U is
the X-ray structure of a Mus musculus P-glycoprotein
[31], an MDR transporter belonging to the ATP-binding
cassette superfamily. ‘Inserts’ that could not be modelled
were removed manually. Models were compared with a
published model for PfMDR1 [32]. The same computa-
tional techniques used for modelling and docking
PfATP6 were used to examine PfMDR1.
Results
Twenty-eight parasites were cultured from travellers
returning with clinical symptoms of malaria betweenApril 2008 and January 2011. Of these 28 patients, only
three had taken any form of prophylaxis. Presenting
parasitaemia from these patients ranged from <0.1% -
28%, with most (25/28) infections acquired in sub-Sa-
haran Africa. All patient information, demographic
details, symptoms, parasitaemia, results of individual
drug sensitivity assays and mutations determined for
each isolate are presented in Additional file 2. Results for
IC50 values are normally distributed for all artemisinins
(p> 0.1). There was no effect on IC50 values of present-
ing parasitaemia or assay method (in vitro versus ex vivo;
p> 0.05 for each artemisinin tested).
Mutational analysis
Several mutations in pfatp6 and pfmdr1 were identified
(see Methods). Of the eight mutational types, three
pfmdr1 mutations (S1034C, N1042D and D1246Y) were
not common enough (≤2 in the dataset) to allow analysis
and are not discussed further. There were 11 (39%) para-
sites with a pfatp6 A623E/S769N haplotype identified
from eight African countries. Of these isolates, all also
contained pfmdr1 Y184F. Two parasites only carried
Y184F and no other mutations in pfatp6 or elsewhere in
pfmdr1. Furthermore, 14 (50%) parasites contained
pfmdr1 N86Y and 9 (32%) parasites had an increased
copy number for pfmdr1 that rounded to a value of 2 (as
described previously [17]). There was no higher order
duplication event (pfmdr1 copy number ≥ 2.5) detected.
Sensitivity comparisons between artemisinins
For each drug the mean (95% CI) IC50 values were 12.3
(10.1 – 14.5), 5.39 (4.34 – 6.44), 3.62 (2.96 – 4.27) and
10.3 (8.09 – 12.5) nM for artemisinin, artesunate, DHA
and artemether, respectively. Results for IC50 values for
different artemisinins were examined for cross-correla-
tions and are summarized in Table 1. Values were mod-
erately or strongly positively correlated for most
comparisons.
Genotypes and artemisinin sensitivity
Parasite IC50 values for artemisinins were compared be-
tween isolates carrying particular mutations (either
pfatp6 A623E/S769N, pfmdr1 N86Y, Y184F or with
increased copy number) and those without. Figure 1
Figure 1 Association of the pfatp6 haplotype (A623E/S769N)
and IC50 values for artemisinin (ART; circles), artesunate (AS;
squares), DHA (triangles) and artemether (AM; diamonds). Mean
individual IC50 values are shown for pfatp6 A623/S769 (open
symbols) and pfatp6 623E/769 N (closed symbols) containing
parasite isolates. The horizontal lines illustrate the mean IC50 values
for each group. *, p= 0.012.
Figure 2 Association of elevated pfmdr1 copy number coupled
with the presence or absence of the pfatp6 haplotype (A623E/
S769N) and IC50 values for artemether. Mean individual IC50
values are shown for non-mutant (pfatp6 A623/S769 and a pfmdr1
copy number of 1 (CN1), open circles) and mutant parasite isolates
containing either pfatp6 623E/769 N and a pfmdr1 copy number of 1
(closed squares), pfatp6 A623/S769 and a pfmdr1 copy number of 2
(CN2, closed triangles) or pfatp6 623E/769 N and a pfmdr1 copy
number of 2 (closed diamonds). The horizontal lines illustrate the
mean IC50 values for each group, with 95% CI values of 5.9-11.6, -4.3-
15.5, 5.2-15.4 and 10.7 to 21.8 for A623/S769/CN1, A623/S769/CN2,
623E/769 N/CN1 and 623E/769 N/CN2, respectively. **, p= 0.0068; *,
p= 0.02.
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artemisinins and pfatp6 haplotype. Resistance to arte-
mether is significantly increased with mutations in
pfatp6 (mean IC50 (95% CI) values of 8.2 (5.7 – 10.7) ver-
sus 13.5 (9.8 – 17.3) nM with a mean increase of 65%;
p = 0.012). Additional file 3 provides 95% CI values for
significant differences between means of IC50 values of
different parasite genotypes.
For parasites with pfmdr1 Y184F mutations that were
present in all A623E/S769N mutants and in 2 additional
parasites, differences in artemether sensitivity were atte-
nuated (p = 0.051). However, differences in sensitivity to
artesunate became apparent with the inclusion of the
two additional parasites with Y184F (mean IC50 (95% CI)
values of 4.4 (3.4 – 5.4) versus 6.5 (4.6 – 8.4) nM with a
mean increase of 48%; p = 0.037; see Additional file 3 and
Additional file 4A).
Increased pfmdr1 copy number was not associated
with changes in sensitivities to artemisinins (see Add-
itional file 4B). The pfmdr1 N86Y mutation was asso-
ciated with increased sensitivity to artemisinin (mean
IC50 (95% CI) values of 14.7 (10.8 – 18.5) versus 10.0 (8.0
– 12.0) nM with a mean decrease of 32%; p = 0.029; see
Additional file 2) and DHA (mean IC50 (95% CI) values
of 4.3 (3.3 – 5.4) versus 2.9 (2.1 – 3.7) nM with a mean
decrease of 33%; p = 0.020; see Additional file 3 and Add-
itional file 4C).
The IC50 values of artemisinins for parasites carrying
pairs of mutations were compared with results fromparasites without those mutations when numbers per-
mitted (Figure 2 and Additional file 5). When interac-
tions between the pfatp6 haplotype and increased copy
number of pfmdr1 were examined together, a highly sig-
nificant association was noted with IC50 values for arte-
mether (mean IC50 (95% CI) values of 8.7 (5.9 – 11.6)
versus 16.3 (10.7 – 21.8) nM with a mean increase of
87%; p = 0.0068; see Additional file 3 and Additional file
5A). A similar significant finding was observed for arte-
sunate (mean IC50 (95% CI) values of 5.1 (4.0 – 6.1) ver-
sus 8.1 (3.9 – 12.2) with an increase of 59%; p = 0.03; see
Additional file 3 and Additional file 5A).
Pfmdr1 N86Y mutations were associated with signifi-
cantly increased sensitivity to DHA when analysed in
isolation of either pfatp6 A623E/S769N (mean IC50 (95%
CI) values of 4.5 (3.3 – 5.7) versus 2.5 (1.4 – 3.7) nM
with a decrease of 44%; p = 0.023; see Additional file 3
and Additional file 5B) or increased pfmdr1 copy number
(mean IC50 (95% CI) values of 4.5 (3.3 – 5.7) versus 2.6
(1.8 – 3.4) nM with a decrease of 42%; p = 0.0087; see
Additional file 3 and Additional file 5C).
Structural analysis of PfATP6 and PfMDR1
Positions 769 and 623 in PfATP6 occur in the N domain,
which is a cytoplasmic putative nucleotide binding
Figure 3 3D models of (A) PfATP6 and (B) PfMDR1. (A) S769 is highlighted in red. The first (K568) and last (C677) residues flanking the
disordered region (which hosts A623) are reported in blue. Notice that the inset presents a zoom of the N domain rotated by 180° (in order to
show the position of the disordered insertion, which is not visible in the model on the left). The predicted artemether binding region is in yellow.
The beta-strand connecting the ATP-binding site to S769 is in green. (B) Blind docking poses for artemisinin, artesunate, DHA, and artemether are
presented as filled spheres. SNPs are highlighted in red sticks. The known drug-binding site is shaded in red.
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dered insert, which is unique in PfATP6. These muta-
tions are displayed in Figure 3A (also see Additional files
6 and Additional file 7 for alignments and evolutionary
conservation) in the model for PfATP6 and are distant
from the predicted artemether binding region [30]. This
suggests that any effects of mutation at these positions
on the interaction with the drug may be mediated
through allosteric mechanisms, which are as yet poorly
understood for PfATP6. Comparison between the bind-
ing modes of different artemisinin derivatives into the
three-dimensional structure of the native PfATP6 sug-
gests that artemether, artemisinin and DHA all interact
in a similar way with the proposed binding site.
The possibility that PfMDR1 modulates sensitivities to
artemisinins also led to modelling of this sequence and
experiments attempting docking with artemisinins. Fig-
ure 3B displays a three-dimensional model for PfMDR1
with the known drug-binding site [31] highlighted in
light red. Visual inspection of the PfMDR1 model sug-
gested conclusions similar to those of Ferreira et al [32]:
namely positions 1034 and 1042 are located in the vicin-
ity of the drug-binding site and S1034C and N1042D
could in principle have a direct role in the drug binding
affinity, whereas SNPs in positions 86 and 184 are more
likely to alter drug sensitivity phenotypes by affecting the
kinetics of the protein and do not seem to have a direct
role in the interaction with the drugs.
Docking experiments on the entire protein (“blind
docking”) showed that the drug-binding cavity is prefer-
entially selected by none of the artemisinins (artemisinin,artemether, DHA, artesunate). “Forced docking” of the
drugs into the protein region surrounding the drug-bind-
ing site (in the red box in Figure 3b) showed that all
molecules are in principle able to establish weak interac-
tions with the residues in the binding cavity but no
“strong” solutions were found for the native PfMDR1
structure. Docking artemisinin, DHA, and artemether
into the mouse MDR1 (MmMDR1) crystal structure (in
a ‘blind’ fashion) also found that, in this case, all mole-
cules displayed a clear preference (90/100 docking solu-
tions) for the drug-binding cavity. This observation,
together with the finding that wild-type PfMDR1 does
not tend to bind artemisinins in such a cavity, suggests
that mutations may confer to PfMDR1 the capability of
transporting artemisinins either by increasing the drug-
binding site affinity to these drugs or by inducing a
pleiotropic rearrangement of the helices involved either
in the drug access to the cavity or in the transport itself.
These mutations may have differential effects on differ-
ent artemisinin derivatives.
Conclusions
This report confirms that increased IC50 values to arte-
mether are linked to the pfatp6 A623E/S769N haplotype.
There are several reasons why this association may be of
interest to those studying mechanisms of drug action
and resistance in malaria. Parasites with this pfatp6
haplotype have originated from dispersed countries in
sub-Saharan Africa (Additional file 2). Most have pre-
sented without obvious drug selection pressure applied
by the traveller, so that it is likely these mutations are
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may therefore be taking place in the countries of origin
for these parasites, by the rapid scale up of anti-malarial
treatment programmes being implemented in recent
years, and now at about 300 million doses of artemisinin
combination therapies disbursed in a year [33,34].
These findings have implications for epidemiological
studies monitoring drug resistance to artemisinins. In
PfATP6, A623E and S769N substitutions have been
reported individually as being associated with elevated
IC50 values to artesunate and artemether respectively
[7,35]. Each of these polymorphisms has also been asso-
ciated with other amino acid substitutions in PfATP6,
but not hitherto with each other (reviewed in [10]).
Combinations of mutations in PfATP6 may result in
more obvious effects on IC50 values, with the haplotype
observed in these studies emerging as being an import-
ant one. Despite the highly polymorphic nature of
PfATP6 [8,12], the independent linkage between arte-
mether and mutations described here confirms previous
observations from French Guiana that these mutations
are worth monitoring in future epidemiological studies
of artemisinin resistance [7]. Other reported mutations
may also prove epidemiologically useful once the intrin-
sic variability of PfATP6 sequence can be distinguished
from those that have relevance to artemisinin sensitivity,
as discussed in detail elsewhere [12].
The magnitude of elevation in IC50 values for arte-
mether in PfATP6 mutant-bearing parasites is approxi-
mately two-fold (Figure 1 and Results). This difference is
larger than between parasites carrying the L263E muta-
tion in PfATP6 when compared with control parasites
(23%), for artemisinin and DHA [36]. Interestingly,
increases in IC50 values for L263E mutants did not apply
to all the artemisinins examined (for example, artesu-
nate) and this also is the case in this study, where arte-
mether is the derivative predominantly affected by these
mutations in PfATP6 (Figures 1 and 2). Mutations in
PfATP6 identified in isolates taken from patients (in con-
trast to L263E) may not fall within protein areas of obvi-
ous functional significance for SERCA type activity that
have been identified in mutagenesis studies over several
decades in many organisms, and by more recent solu-
tions of crystal structures [37–39]. They are located in
less highly conserved regions, so this may reflect ignor-
ance of structure-function relationships in polymorphic
plasmodial proteins that contain low complexity ‘inserts’,
as suggested almost two decades ago [40]. These studies
also illustrate some difficulties in developing laboratory
models of drug resistance with transgenic parasites be-
cause resistance phenotypes may be difficult to identify
in some contexts. For example, resistance observed with
K76T pfcrt for chloroquine, may depend on genetic con-
text [41]. Part of this genetic context includes the pfmdr1gene, which itself can modulate in vitro sensitivity to a
variety of unrelated drug classes (reviewed in [42]).
Duplication in pfmdr1 has emerged as being perhaps
surprisingly common in these returning travellers. Previ-
ous reports from African countries have only demon-
strated sporadic instances of pfmdr1 gene duplication.
Duplications can arise within the host after drug treat-
ment as well as being selectable in vitro ([20,43,44] sug-
gesting that the potential for this genetic event to occur
is high. This is borne out by the correspondingly high
prevalence of pfmdr1 duplications in parasites in coun-
tries that have used arylaminoalcohols such as meflo-
quine as part of their anti-malarial treatment regimens
(e.g. [17]) as well as the ease for selection of increased
copy number in African parasites [45].
There may be a strong association between duplica-
tions in pfmdr1 and mutations in pfatp6 that influence
the IC50 values for artemether (and artesunate), because
even in a relatively small subset of parasites, there is a
highly significant link between mutations in both trans-
porter genes and IC50 values. This association is not ap-
parent with pfmdr1 duplications alone in this relatively
small dataset, although it has been noted before in larger
studies of field isolates in different regions of the world
(e.g. [17]), and also in laboratory models [21,46-48].
Several studies have reported on mutations in pfatp6
and pfmdr1 gene duplications or polymorphisms as part
of epidemiological monitoring for drug resistance, in-
cluding for resistance to artemisinins. Interestingly, some
studies may only be able to provide useful information
when parasites are cultured for the short term ex vivo
because of mixed populations of parasites with and with-
out mutations in pfatp6 and associated fitness costs of
mutations. These can result in disappearance of pfatp6
mutations after adaptation to continuous culture, as
carefully documented previously [9]. Artemisinin or arte-
sunate IC50 values are almost double in field isolates
from Southeast Asia with gene duplications, whereas in
these studies there is no significant change in IC50 values
to DHA [17,49,50]. Mutations in the 3’ sequence of
pfmdr1 (with D1246Y being a good example) increase
sensitivity to artemisinin [51–53], whereas they may
affect artesunate in the opposite way, by decreasing sen-
sitivity in field isolates [17]. One of the strongest associa-
tions is between the N86Y substitution and increased
sensitivity to artemisinin and DHA in this analysis. This
finding is consistent with previous reports that this mu-
tation in pfmdr1 may modulate the effects of
artemisinins.
PfMDR1 is localized to the food vacuole of parasites,
and studies after heterologous expression suggest that
SNPs alter substrate specificity for aminoquinolines and
arylaminoalcohols [54] with the suggestion that drugs
are removed from the cytoplasm into the food vacuole
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values to artemisinins by modulating their removal (to
the food vacuole) away from their proposed target
(PfATP6 localised in the ER). A simple hypothesis that
highlights the importance of interactions between
PfATP6 and PfMDR1 in modulating artemisinin sensitiv-
ity is that resistant parasites carrying mutations in
PfATP6 can become sensitive if SNPs in PfMDR1 de-
crease delivery of artemisinins to the food vacuole. This
suggestion is consistent with results from modelling sug-
gesting that mutations in PfATP6 are unlikely to differ-
entially affect interactions with different artemisinins and
PfATP6, whereas PfMDR1 mutations may have variable
effects on transport of artemisinins.
These insights into the biology of drug resistance
mechanisms have developed from an analysis that com-
bines results from field isolates with contributions from
molecular studies including modelling. Studies of return-
ing travellers as ‘sentinels’ for drug resistance may be par-
ticularly useful, as previously pfmdr1 gene duplication in
Africa was first recorded in a returning traveller [56]. For
epidemiological purposes, monitoring for mutations in
both transporter genes (pfatp6 and pfmdr1) should be
carried out and related to in vitro sensitivity profiles of
the clinically relevant artemisinin derivatives.Additional files
Additional file 1. Pyrosequencing primers
Additional file 2. Patient information, demographic details, symptoms,
parasitemia, results of individual drug sensitivity assays and mutations
determined for 28 P. falciparum isolates collected from returning
travellers. Excel file
Additional file 3. Mean differences and 95% CI of mean differences
between comparisons of IC50 values that are significantly associated with
particular parasite genotypes (see Results and Additional files 4 and 5)
Additional file 4. Association of pfmdr1 haplotypes, Y184F (A), N86Y (B)
and copy number (CN1/2; C) and IC50 values for artemisinin (ART; circles),
artesunate (AS; squares), DHA (triangles) and artemether (AM; diamonds).
Mean individual IC50 values are shown for non-mutant (open symbols)
and mutant (closed symbols) containing parasite isolates. The horizontal
lines illustrate the mean IC50 values for each group. *, p < 0.05
Additional file 5. Association of (A) pfatp6 haplotype at 623/769 versus
pfmdr1 copy number (CN), (B) pfatp6 haplotype at 623/769 versus
pfmdr1haplotype at 86 and (C) pfatp6 haplotype at 623/769 versus
pfmdr1 haplotype at 86 and IC50 values for artemether (ART), artesunate
(AS), DHA and artemether (AM). Mean individual IC50 values are shown
for non-mutant (open circles) and mutant parasite isolates containing
either single mutation (closed squares and triangles) or both (closed
diamonds). The horizontal lines illustrate the mean IC50 values for each
group. **, p < 0.01; *, p < 0.05
Additional file 6. Sequence alignments of PfATP6 with the human,
rabbit, and schistosomal homologues. The two positions at which SNPs
were observed (623 and 769) are highlighted with red-filled circles and
the artemether binding regions are in grey boxes
Additional file 7. Multiple sequence alignments of the ATP N-domain of
PfATP6 with its homologues.The top part of the alignment presents the
conservation level along the PfATP6 sequenceobserved in PfATP6 variants. The bottom part of the alignment presents
the conservation level along the PfATP6 sequence observed with its
homologues. The higher the column, the more conserved a residue is in
the corresponding position. Columns are coloured according to the
residue’s chemical properties: cysteines in yellow, aliphatic hydrophobics
(V, L, I, M) in green, aromatic amino acids (Y, F, W) in dark green, small
amino acids (G, A, S, T) in light grey, negatively charged (D, E) in blue,
polar (N, Q) in magenta, histidines in orange, positively charged (K, L) in
red, prolines in grey. The black bar in the middle shows the column score
between the query sequence and the homologous amino acid
distributions with |, +, ., -, = indicating scores from 'very good' to 'very
bad'. The ATP binding residue positions are indicated with red arrows
and positions 623 and 769 with black arrows. The insertions unique to P.
falciparum can be easily recognized where the alignment lacks the
bottom part and the black bar (the homologue information
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